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Abstract
Background: Fibrosis of the extracellular matrix (ECM) in dilated cardiomyopathy (DCM) is com-
mon and compromises both systolic and diastolic function. The aim of this study was to investigate the 
kinetics of ECM fibrosis markers over a 12 month follow-up in patients with DCM based on the severity 
of diastolic dysfunction (DD). 
Methods: Seventy consecutive DCM patients (48 ± 12.1 years, ejection fraction 24.4 ± 7.4%) were 
included in the study. The grade of DD was determined using the ASE/EACVI algorithm. Markers 
of ECM fibrosis were measured at baseline and at 3 and 12 month follow-ups: collagen type I and III 
(PICP, PINP, PIIICP, PIIINP), transforming growth factor beta-1 (TGF1-b), connective tissue growth 
factor (CTGF) and galectin-3 were measured. 
Results: Patients were divided into three groups according to DD severity: 30 patients with grade I,  
18 with grade II and 22 with grade III of DD. Levels of PICP, PINP were increased over a 12-month 
period, while PIIINP decreased and PIIICP unchanged. Levels of TGF1-b decreased from the 3 to the 
12-month points in grade I and II DD, and in grade III they remained unchanged. Levels of CTGF 
decreased over 12 months in grade III DD but were unchanged in grades I and II. Galectin-3 levels 
remained the same over all observation periods, irrespective of DD grade. 
Conclusions: Regardless of the DD grade, markers of collagen type I synthesis increased, markers 
of collagen type III decreased. Levels of TGF and CTGF had a tendency to decrease. Galectin-3 was 
revealed not to be a marker discriminating the severity of DD. (Cardiol J XXX; XX, X: xx–xx)
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Introduction
The prevalence of heart failure (HF) is 1–2% 
of the adult population in developed countries [1]. 
According to the current classification of diastolic 
dysfunction (DD), virtually all patients with HF 
with reduced ejection fraction (HFrEF) have at 
least a mild degree of DD [2]. Irrespective of HF 
etiology, e.g. ischemic or non-ischemic, progressive 
abnormalities in the extracellular matrix (ECM) 
result in a gradual worsening of both systolic and 
diastolic function. Reactive fibrosis of ECM typi-
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cally is observed in dilated cardiomyopathy (DCM) 
and importantly contributes to HF progression. 
Altered components of ECM, e.g. relative increase 
of collagen type I over III, leads to the stiffening of 
the myocardium and further worsening DD. Thus, 
ECM fibrosis and DD seems to be interrelated. 
Extracellular matrix fibrosis can be studied 
directly by means of endomyocardial biopsy or 
non-invasively with magnetic resonance. Further-
more, measurement of serum markers of fibrosis 
may provide insight into myocardial pathology. The 
dynamics of collagen turnover may be studied via 
circulating markers of collagen synthesis which are 
released into the bloodstream during conversion 
into the mature collagens [3–5]. In addition, levels 
of fibrosis controlling factors, including transform-
ing growth factor beta-1 (TGF1-b), connective 
tissue growth factor (CTGF) or galectin-3 may 
also indicate ongoing ECM fibrosis [6]. Numerous 
studies have explored the role of serum markers of 
fibrosis in various cardiac disorders, including HF, 
DCM and hypertension. In the majority of these 
studies only single measurements of markers of 
interests were performed and, based on those 
baseline values, associations were investigated. 
Conversely, a minority of studies examined for the 
kinetics of those markers, which may be equally 
important as patterns of biomarkers over time may 
be more relevant than single measures. 
Under a previous investigation, 12-month ki-
netics of serum markers of collagen synthesis, TGF 
and CTGF, in DCM patients were stratified accord-
ing to duration of disease and fibrosis status [7]. 
Different patterns of these markers were observed 
over time in patients with and without ECM fibro-
sis. Despite an extensive literature search, no stud-
ies were found exploring the relationship between 
the kinetics of serum markers and DD in patients 
with DCM. Therefore, in this study, the aim was to 
investigate changes over time in selected markers 
of fibrosis in DCM patients stratified on the basis 
of DD over a 12-month observation period. 
Methods
Study groups 
From July 2014 to October 2015, 70 consecu-
tive patients with DCM were included. DCM was 
diagnosed according to the current European 
Society of Cardiology 2007 guidelines after exclu-
sion of significant coronary artery disease, primary 
heart valve disease, congenital heart disease and 
arterial hypertension [8]. All patients were in the 
New York Heart Association (NYHA) class I–III 
for at least 2 preceding weeks.  An assessment of 
patient status, echocardiographic examinations and 
blood sampling were repeated at 3 and 12 months. 
The study protocol was approved by the relevant 
institutional committees and ethics committees. 
All patients gave written informed consent prior to 
inclusion in the study. During the study, 4 (5.7%) 
patients died within the first 3 months and another 
2 (3%) within 12 months. Thus, there were 64 
(94.3%) patients which comprised follow-up data.
Echocardiography
All measurements, including DD assessment, 
were performed according to the recommendations 
of the European Associations of Cardiovascular Im-
aging (EACVI) [2]. Based on the EACVI algorithm, 
DCM patients were divided into three groups; 
grade I, II or III DD.
Laboratory measurements
Venous blood samples and laboratory testing 
of serum markers of fibrosis were conducted us-
ing methods described in recent papers [9]. The 
concentrations of collagen synthesis markers and 
fibrosis controlling markers were determined in 
plasma using a commercially available ELISA tests 
as follows: collagen type 1 (manufacture reference 
values 46.7–178.9 pg/mL), procollagen I N-terminal 
propeptide (PINP 30.2–55.1 pg/mL), procollagen 
III N-terminal propeptide (PIIINP 2.69–63.56 ng/
mL), procollagen I C-terminal propeptide (PICP 
64–186 pg/mL = 0.064–0.186 ng/mL), procol-
lagen III C-terminal propeptide (PIIICP 5.2–35.5 
ng/mL), connective tissue growth factor (CTGF 
2.3–42.5 ng/mL) (all from Cloud Clone Corp. Hou-
ston, TX, USA); TGF1-b (4.639–14.757 pg/mL = 
4.639–14.757 ng/mL) (Diaclone SAS, Besancon 
Cedex, France), galectin-3 (4–114 ng/mL) (Abbott 
Diagnostics, Vienna, Austria). All measurements 
were performed by technicians blinded to the sam-
ple status. Intra-assay and inter-assay coefficients 
of variation were < 7%.
Statistical analysis
The normality of distribution of variables was 
assessed with the Shapiro-Wilk test. Comparisons 
of clinical parameters in the three groups were 
conducted with the Kruskal-Wallis ANOVA non-
parametric analysis of variance, with repeated 
measurements since differences between the 
time-points were not distributed normally. A post-
hoc analysis was conducted with the Dunnett test 
which is designed for heterogeneous covariance. 
All results were considered statistically significant 
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when p value was < 0.05. Statistical analysis was 
conducted with Statistica version 13.1 software. 
Results
Baseline characteristics
Table 1 shows the baseline characteristics of 
patients in the three groups of patients stratified 
according to DD grade. Patients with grade II 
DD had significantly larger left ventricular end-
systolic diameter as assessed by body surface area 
(34.1 mm/m2), while there were no differences 
in patients with grade I and III DD. E-wave and 
A-wave had significantly higher values in grade 
II and grade III DD in comparison to grade I DD 
while E/A ratio was highest in patients with grade 
III DD [2, 9]. There were no differences in age, 
gender, NYHA classification or body mass index 
between the groups. Patients with grade I DD had 
the highest concentration of hemoglobin (15.1 g/
dL), while patients with grade II and grade III DD 
had significantly higher level of amino-terminal 
pro B-type natriuretic peptide (5627.8 pg/mL 
and 6802 pg/mL, respectively). No differences 
were observed in the frequency of sinus rhythm, 
atrial fibrillation or duration of QRS between the 
groups. All patients were receiving optimal HF 
pharmacotherapy but patients with grade III DD 
Table 1. Baseline characteristics of the study population divided according to diastolic dysfunction grade. 
Parameter Diastolic dysfunction P
Grade I Grade II Grade III 
Number 30 18 22
Age [years] 48.4 (42–53) 47.61 (39–56) 47.96 (36–61) 0.99
Sex (male/female) 27/3 18/0 18/4 0.16
BMI [kg/m2] 28.166 (24.5–31.2) 25.3 (21–30) 27.6 (22.3–30.9) 0.16
NYHA class (I–IV) 2.37 ± 0.76 2.57 ± 0.73 2.77 ± 0.61 0.08
LVESD/BSA [mm/m2] 27.6 (24.4–30.5)*** 34.10 (26–39) 31.43 (29.3–35.5) 0.01
LVEDD/BSA [mm/m2] 33.9 (29.5–36) 39.7 (33–43.5) 35.99 (32.2–40.5) 0.06
E-wave [m/s] 0.6 (0.48–0.7)*** 0.79 (0.62–0.9) 0.94 (0.77–1.04)* 0.00
A-wave [m/s] 0.7 (0.6–0.76)*** 0.44 (0.34–0.59) 0.34 (0.25–0.4)* 0.00
E/A ratio 0.86* 1.43 2.9** 0.00
LVEF [%] 26.4 (20–33) 23.39 (17–30) 22.46 (17–25) 0.14
ECG rhythm sinus/AFL/ 
/cardiac stimulator
26/4/0 11/5/2 19/2/1 0.06
QRS complex [ms] 103.67(80–120) 115.56(80–140) 22.46 (17–25) 0.14
Hemoglobin [g/dL] 15.10 (14.6–16.0)*** 13.76 (12.6–15.2) 14.1 (13.2–15) 0.004
Creatinine [µmol/L] 83.43 (68–96) 92.11 (72–112) 114.41 (13.2–15) 0.07
eGFR [mL/min] 94.07 (81–107) 82.19 (65.5–102) 76.3 (57–104) 0.04
NT-proBNP [pg/mL] 1917 (296–1898)*** 5627.8 (1736–5060) 6802 (1211–4924)* 0.00
Beta-blocker 29 (96.7%) 18 (100%) 22 (100%) 0.51
ACEI/ARB 28 (93.3%)/1 (6.7%) 16 (88.9%)/1 (1.1%) 22 (100%)/0 (0%) 0.31/0.57
MRA 28 (93.3%) 18 (100%) 20 (90.9%) 0.45
Furosemidum 9 (30%)*** 15 (83.3%) 17 (77.3%)* 0.00
Vitamin K antagonist 1 (6.7%) 0 (0%) 1 (4.5%) 0.68
NOAC 3 (10%) 3 (16.7%) 1 (4.5) 0.45
ICD/CRT-D 7 (23.3%) 10 (55.6%) 9 (40.9%) 0.13
*p-values for comparison between grades I, II, and III diastolic dysfunction (DD): p < 0.05 (grade I DD vs. grade III DD); **p-values for compar-
ison between grades I, II, and III diastolic dysfunction (DD): p < 0.05 (grade II DD vs. grade III DD); ***p-values for comparison between grade 
I, II, and III diastolic dysfunction (DD): p < 0.05 (grade I DD vs. grade II DD); ACEI — angiotensin converting enzyme inhibitor; AFL — atrial flut-
ter; ARB — angiotensin receptor type 1 blocker; A-wave — late mitral inflow velocity; BMI — body mass index; CRT-D — cardiac resynchroni-
zation therapy with cardioverter-defibrillator; E/A — ratio of early mitral inflow E-wave and late mitral inflow A-wave velocity; ECG — electro-
cardiogram; eGFR — estimated glomerular filtration rate; E-wave — early mitral inflow velocity, ICD— implantable cardioverter-defibrillator; 
LVEDD/BSA — indexed to body surface area left ventricular end-diastolic diameter; LVEF — left ventricular ejection fraction; LVESD/BSA 
— indexed to body surface area left ventricular end-systolic diameter; MRA — mineralocorticoid receptor antagonist; NOAC — non-vitamin K 
antagonist oral anticoagulants; NT-proBNP — amino-terminal pro B-type natriuretic peptide; NYHA — New York Heart Association class 
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required a loop diuretic more often. There were 
also no differences in implantable cardioverter-
defibrillator or cardiac resynchronization therapy 
with cardioverter-defibrillator implantations be-
tween groups. 
Kinetics of the serum markers of fibrosis in 
patients with grade I diastolic dysfunction
Baseline, 3 and 12-month levels of serum 
markers of collagen synthesis, TGF1-b, CTGF 
and galectin-3 in patients with DD grade I are 
presented in the Figure 1. Blood levels of mark-
ers of collagen type I synthesis (PICP and PINP) 
consistently increased from baseline to the 3- and 
12-month observation points. In contrast, dy-
namics of markers of collagen type III synthesis 
behaved in the opposite manner. Changes in mark-
ers of collagen type III synthesis (PIIICP) were 
not significant, whereas PIIINP levels decreased 
during the observation period. TGF1-b values 
were unchanged from baseline to the 3-month 
time-point but decreased significantly between 
the 3- and 12-month time-point. Finally, levels 
of CTGF and galectin-3 did not change over the 
observational period.
Kinetics of the serum markers of fibrosis in 
patients with grade II diastolic dysfunction
Baseline, 3- and 12-month levels of serum 
markers of collagen synthesis, TGF1-b, CTGF 
and galectin-3 in patients with DD grade I are 
presented in Figure 2. Blood levels of collagen 
type I synthesis marker — PICP consistently 
increased from baseline to the 3- and 12-month 
time-points, whereas PINP increased from the 3- to 
12-month time-point. Markers of collagen type III 
synthesis, PIIICP and PIIINP, behaved differently. 
PIIICP increased significantly over the period of 
observation but PIIINP decreased over a longer 
observation period between 3 to 12 months. TGF1-
b blood levels did not differ between baseline and 
3-month follow-up, however it decreased between 
3- and 12-month time-points. Levels of CTGF and 
galectin-3 remained unchanged over 12-months of 
observation.
Kinetics of the serum markers of fibrosis in 
patients with grade III diastolic dysfunction
Baseline, 3- and 12-month levels of serum 
markers of collagen synthesis, TGF1-b, CTGF 
and galectin-3 in patients with DD grade I are 
presented in the Figure 3. Levels of markers of 
collagen type I synthesis PICP and PINP remained 
unchanged from baseline to 3-month time-point 
but both increased between 3- and 12-month time-
points. Changes in PIIICP were not significant, 
whereas values of PIIINP significantly decreased 
over a longer period of observation from baseline 
to 12 months and from 3 to 12 months. TGF1-b 
blood levels remained unchanged over 12 months 
of observation, whereas CTGF levels decreased 
between baseline and 12 months. Finally, levels of 
galectin-3 did not differ between baseline, 3- and 
12-month time-points.
Figure 1. Comparison of baseline, 3- and 12-month se-
rum levels of procollagen type I carboxy-terminal pep-
tide (PICP) in patients with different diastolic dysfunc-
tion (DD) grades.
Figure 2. Comparison of baseline, 3- and 12-month se-
rum levels of procollagen type I amino-terminal peptide 
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Comparison of kinetics of serum markers 
of fibrosis between patients with various 
grades of diastolic dysfunction 
In general, the kinetics of markers of collagen 
type I and III synthesis did not differ between pa-
tients with different DD grades, e.g. markers of col-
lagen type I synthesis (PICP, PINP) increased (Figs. 
1, 2), whereas markers of collagen type III synthe-
sis (PIIINP) decreased over the 12-month period 
of observation regardless of DD grade (Fig. 3). 
However, it should be noted that the baseline 
values of PIIICP were higher and similar in grade 
I and grade III DD in comparison to patients with 
grade II DD (Fig. 4). Conversely, levels of PINP 
at the 3 months were significantly higher in grade 
I compared to grade II and III DD. Blood levels 
of TGF1-b and CTGF did not differ at baseline, 
at 3- and 12-months of observation, regardless of 
DD grade. The kinetics of TGF1-b were initially 
unchanged (during the first 3 months) of observa-
tion and then decreased (between 3 to 12 months) 
in patients with grade I and II DD, but the kinetics 
did not change during the observation period in 
patients with grade III DD (Fig. 5). The kinetics 
of CTGF were similar in patients with different 
DD grades and, while levels had a tendency to de-
crease, significant changes could only be observed 
in patients with grade III DD (Fig. 6). Finally, ga-
lectin-3 levels did not differ between patients with 
different DD grades either at baseline nor at 3- and 
12-month observational points (Fig. 7).
Correlations between serum markers of  
fibrosis and diastolic function parameters
A weak negative correlation was observed 
between baseline serum levels of PINP and base-
line left atrial volume index (LAVI) (r = –0.3; 
p < 0.05) and between baseline PINP and LAVI 
at 3 months (r = –0.29; p < 0.05). At 12 months, 
there was a moderate correlation between PINP 
and E/A ratio (r = 0.46; p < 0.05). As mark-
ers of collagen type III synthesis, PIIINP nega-
Figure 3. Comparison of baseline, 3- and 12-month se-
rum levels of procollagen type III amino-terminal pep-
tide (PIIINP) in patients with different diastolic dysfunc-
tion (DD) grades.
Figure 4. Comparison of baseline, 3- and 12-month 
serum levels of procollagen type III carboxy-terminal 



































Figure 5. Comparison of baseline, 3- and 12-month se-
rum levels of transforming growth factor beta-1 (TGF1-b) 
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tively correlated with E/E’ ratio and E’ (r = –0.4 
and r = –0.34; p < 0.05) at 3 months and with E’ at 
12 months (r = –0.31; p < 0.05), whereas PIIICP at 
12 months correlated with E/E’ and LAVI (r = 0.34; 
r = 0.36; p < 0.05, respectively). TGF1-b at 
baseline correlated with LAVI (r = –0.33; p < 
0.05). CTGF at 3 months correlated with E/E’ at 
12 months (r = 0.3; p < 0.05) and CTGF at 12 
months correlated with E/E’ at 12 months (r = 0.31; 
p < 0.05). Galectin-3 at baseline correlated 
with tricuspid regurgitation velocity and E-wave 
(r = 0.3 and r = 0.26; p < 0.05, respectively). 
Galectin-3 at 3 months correlated with 3-month 
E’ velocity (r = 0.42; p < 0.05) and between 
3-month and baseline E/A ratio and tricuspid 
regurgitation velocity (r = 0.28; p < 0.05 and 
r = 0.27; p < 0.05, respectively).  
Discussion
Kinetics of collagen synthesis markers in 
patients with various grades of diastolic 
dysfunction
The process of ECM fibrosis in DCM has 
been extensively studied. However, the kinetics 
of collagen synthesis markers and its relationship 
to DD are poorly understood. While several papers 
discussed selected markers of fibrosis and the de-
velopment of DD, few refer to DD in DCM. The 
present study is the first to report that long term 
(12th-month period) synthesis of collagen type I is 
enhanced, whereas synthesis of collagen type III is 
diminished in DCM patients, regardless of diastolic 
dysfunction degree. Intuitively, it may be thought 
that patients with more advanced DD (restrictive 
filling) have higher collagen synthesis but in fact 
collagen type I synthesis is uniformly increased 
in all DD groups. Collagens types I and III have 
different physical properties, e.g. collagen type I 
has a higher tensile strength and collagen type III 
is more elastic and complaint [10, 11]. Thus, an in-
crease in collagen type I may contribute to further 
worsening of DD. Consequently, collagen I and III 
ratios remained the same in patients with various 
DD grades. Of note, among markers of collagen 
type III synthesis (PIIICP and PIIINP), only PIIINP 
levels significantly decreased during the whole 
period, while PIIICP behaved differently, with a 
tendency to decrease and only increase in grade II 
DD. This observation cannot be easily explained, 
but it should be emphasized that only PIIINP is a 
truly proven marker of collagen synthesis, while 
the role of PIIICP is less clear [12]. 
Few studies have demonstrated the relation-
ship between markers of collagen synthesis and 
DD under differing cardiac conditions. The most 
frequently described marker, which exhibited an 
association with DD was PICP. Demir et al. [13] 
has shown that hypertensive patients with DD 
had a significantly higher serum level of PICP 
compared to those without DD. Another group 
reported that the serum level of PICP was related 
to DD in patients with early stage type 2 diabetes 
mellitus [14]. Roongsritong and colleagues also 
described the relationship between PICP and DD 
in elderly patients [15]. It should be emphasized 
that those studies reported associations between 
Figure 7. Comparison of baseline, 3- and 12-month se-
rum levels of galectin-3 in patients with different dia-
stolic dysfunction (DD) grades.
Figure 6. Comparison of baseline, 3- and 12-month se-
rum levels of connective tissue growth factor (CTGF) in 
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particular markers of fibrosis and DD but no re-
lationships were found between those markers 
and degree of DD. Only a few researchers have 
discussed this issue. Roongsritong et al. [16] has 
shown that PICP was related to the severity of DD 
in patients with HFrEF. They observed that the 
PICP level was significantly higher among patients 
with a more severe degree of DD compared to 
those with less severe DD. In the present study, 
no correlation was observed  between PICP and 
DD grade. However, it should be noted that the 
authors used a currently outdated approach to DD 
classification and consequently compared only 
two groups of patients with non-severe (mild to 
moderate) and severe DD [16]. Therefore, from 
a methodological point of view it is impossible to 
compare the results of the present study to those 
observed by Roongsritong et al. [16]. The cur-
rent observations showed that PINP correlated 
with the E/A ratio, a crucial parameter in the DD 
algorithm. This may suggest that patients with 
advanced DD and a higher E/A ratio had a higher 
level of PINP. Further, Rossi et al. [17] compared 
serum levels of PIIINP between three groups with 
DD with non-restrictive, reversible restrictive 
and irreversible restrictive filling patterns. The 
authors observed that PIIINP was significantly 
higher in patients with a restrictive mitral inflow 
pattern [17]. However, the classification of patients 
according to mitral inflow pattern, described in 
the cited study, varies from the current grading of 
DD. In addition to the fact that this classification 
of DD is no longer used, the authors compared 
unmatched patient groups, with 9 patients having 
restrictive versus 88 patients having a non-restric-
tive filling pattern. In the present study, a negative 
correlation between PIIINP and E/E’ ratio was 
demonstrated. This may suggest that patients 
with grade I DD and a lower E/E’ ratio had higher 
serum levels of PIIINP. This observation seems 
accurate, since a heart muscle rich in collagen III 
is characterized by greater flexibility and elasticity 
and therefore has an improved diastolic function. 
Kinetics of TGF, CTGF and galectin-3  
in patients with various diastolic  
dysfunction grades
Levels of TGF1-b were similar regardless of 
the DD grade and the kinetics of TGF1-b did not 
differ between the subgroups. Numerous studies 
have confirmed that TGF and its downstream me-
diator — CTGF are crucial molecules stimulating 
cardiac fibrosis [18]. Thus, one may speculate that 
TGF1-b would be highest in patients with grade 
III DD. However, observed herein was that TGF 
levels were similar in all three DD groups. One pos-
sible explanation is that serum levels of TGF are 
not equivalent to the expression of TGF in the myo-
cardium [19]. Additionally, not all of TGF1-b but 
only its active forms are involved in biological pro-
cesses, and, as confirmed earlier, levels of TGF1-b 
and its active metabolites may not be correlated 
[20]. Conversely, the pro-fibrotic mechanisms 
of TGF1-b includes not only differentiation of 
cardiac fibroblasts to myofibroblasts, which have 
higher activity for collagen production, but also a 
differentiation throughout its effector cytokine — 
CTGF [21, 22]. In the present study, serum levels 
of CTGF did not differ significantly between the 
subgroups but a positive correlation was observed 
between CTGF and E/E’ ratio. This may suggest 
that patients with more advanced DD (higher E/E’ 
ratio) had higher levels of CTGF. Wu et al. [23] 
reached similar conclusions and demonstrated that 
serum levels of CTGF were the highest among 
patients with severe DD. With respect to the 
12-month kinetics of CTGF levels were found to 
decrease homogenously in all patients regardless 
of DD severity but significant changes were only 
observed in grade III of DD. 
Galectin-3 plays an important role in the patho-
genesis of left ventricular remodeling [24]. Only 
a few studies have examined the relationship be-
tween galectin-3 and DD in HF. Wu et al. [25] report-
ed correlations between plasma galectin-3 and E/E’ 
in advanced HFpEF. Gurel et al. [26] demonstrated 
that galectin-3 was an independent predictor of DD 
in patients with end-stage renal failure undergoing 
dialyses. Another study compared serum levels 
of galectin-3 in patients with HFrEF and HFpEF 
and demonstrated that it was higher in patients 
with HFrEF and correlated with E/E’ ratio [27]. 
Observed herein, was that galectin-3 levels were 
similar regardless of DD grade and remained stable 
over 12 months. However, a positive correlation 
between galectin-3 and E’-wave which reflects the 
rate of myocardial relaxation [28] was also observed. 
Nevertheless, based on  the analysis, serum levels 
of galectin-3 seemed not to be a good marker of DD 
severity in DCM. One possible explanation could be 
that circulating galectin-3 does not correlate with its 
myocardial expression as has been recently reported 
by Besler et al. [29].
In summary, 12-month kinetics of fibrosis 
controlling molecules (TGF, CTGF, and galectin-3) 
were similar in three DD groups. Furthermore, 
the pattern of TGF and CTGF was the same and 
decreasing, and as such is probably not a good 
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target for eventual anti-TGF or anti-CTGF agents, 
provided that blood expression of those molecules 
have any relations with their myocardial counter-
parts or fibrosis progression, which at present is 
uncertain. What is more, it should be reiterated that 
the fact that none of the seven markers of fibrosis 
under study turned out to have a different pattern 
in all three DD groups and thus, none can serve as 
a marker of DD degree.
Limitations of the study
There are several potential limitations to this 
study. The division of DCM patients was based on 
the current DD classification, resulting in relatively 
small subgroups, which may have impacted statis-
tical relevance. As reported in previous studies, 
serum levels of ECM fibrosis markers might not 
reflect their myocardial expression and thereby may 
only be weakly correlated with myocardial function. 
Conclusions
Twelve-month kinetics of serum markers of 
fibrosis in DCM patients with various grades of 
DD is characterized with similar patterns. Regard-
less of the DD grade, markers of collagen type I 
synthesis increased and markers of collagen type 
III decreased (mainly PIIINP). Levels of TGF and 
CTGF had a tendency to decrease over the obser-
vation period, whereas kinetics of galectin-3 was 
stable. This observation may indicate that the pres-
ence of myocardial fibrosis is just one component, 
among others, that affects DD. 
Acknowledgements
This work was funded through the National Sci-
ence Center, Poland (Grant 2013/09/D/NZ5/00252) 
and the Department of Scientific Research and 
Structural Funds of Medical College, Jagiellonian 
University (Grant K/ZDS/004596). 
Conflict of interest: None declared
References
1. Ponikowski P, Voorse AA, Anker SD, et al. 2016 Guidelines for 
the diagnosis and treatment of acute and chronic heart failure. 
Eur J Heart Fail. 2016; 18: 891–975.
2. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations 
for the Evaluation of Left Ventricular Diastolic Function by Echo-
cardiography: An Update from the American Society of Echocar-
diography and the European Association of Cardiovascular Imag-
ing. J Am Soc Echocardiogr. 2016; 29(4): 277–314, doi: 10.1016/j.
echo.2016.01.011, indexed in Pubmed: 27037982.
3. Rubiś P, Totoń-Żurańska J, Wiśniowska-Śmiałek S, et al. Right 
ventricular morphology and function is not related with microR-
NAs and fibrosis markers in dilated cardiomyopathy. Cardiol J. 
2017 [Epub ahead of print], doi: 10.5603/CJ.a2017.0099, indexed 
in Pubmed: 28840590.
4. Querejeta R, López B, González A, et al. Increased collagen 
type I synthesis in patients with heart failure of hypertensive 
origin: relation to myocardial fibrosis. Circulation. 2004; 110(10): 
1263–1268, doi: 10.1161/01.CIR.0000140973.60992.9A, indexed 
in Pubmed: 15313958.
5. Klappacher G, Franzen P, Haab D, et al. Measuring extracel-
lular matrix turnover in the serum of patients with idiopathic or 
ischemic dilated cardiomyopathy and impact on diagnosis and 
prognosis. Am J Cardiol. 1995; 75(14): 913–918, doi:  10.1016/
s0002-9149(99)80686-9.
6. Dobaczewski M, Chen W, Frangogiannis NG. Transforming 
growth factor (TGF)-b signaling in cardiac remodeling. J Mol Cell 
Cardiol. 2011; 51(4): 600–606, doi: 10.1016/j.yjmcc.2010.10.033, 
indexed in Pubmed: 21059352.
7. Rubiś P, Wiśniowska-Smiałek S, Wypasek E, et al. 12-month 
patterns of serum markers of collagen synthesis, transforming 
growth factor and connective tissue growth factor are similar in 
new-onset and chronic dilated cardiomyopathy in patients both 
with and without cardiac fibrosis. Cytokine. 2017; 96: 217–227, 
doi: 10.1016/j.cyto.2017.04.021, indexed in Pubmed: 28460256.
8. Lang R, Badano L, Mor-Avi V, et al. Recommendations for Car-
diac Chamber Quantification by Echocardiography in Adults: An 
Update from the American Society of Echocardiography and the 
European Association of Cardiovascular Imaging. Eur Heart J Car-
diovasc Imaging. 2015; 16(3): 233–271, doi: 10.1093/ehjci/jev014.
9. Rubiś P, Wiśniowska-Śmialek S, Wypasek E, et al. Fibrosis of 
extracellular matrix is related to the duration of the disease but is 
unrelated to the dynamics of collagen metabolism in dilated car-
diomyopathy. Inflamm Res. 2016; 65(12): 941–949, doi: 10.1007/
s00011-016-0977-3, indexed in Pubmed: 27516211.
10. Marijianowski MM, Teeling P, Mann J, et al. Dilated cardiomy-
opathy is associated with an increase in the type I/type III col-
lagen ratio: a quantitative assessment. J Am Coll Cardiol. 1995; 
25(6): 1263–1272, doi: 10.1016/0735-1097(94)00557-7, indexed 
in Pubmed: 7722119.
11. Pauschinger M, Knopf D, Petschauer S, et al. Dilated cardiomy-
opathy is associated with significant changes in collagen type 
I/III ratio. Circulation. 1999; 99(21): 2750–2756, indexed in 
Pubmed: 10351968.
12. Izawa H, Murohara T, Nagata K, et al. Mineralocorticoid receptor 
antagonism ameliorates left ventricular diastolic dysfunction and 
myocardial fibrosis in mildly symptomatic patients with idiopathic 
dilated cardiomyopathy: a pilot study. Circulation. 2005; 112(19): 
2940–2945, doi:10.1161/CIRCULATIONAHA.105.571653, inde-
xed in Pubmed: 16275882.
13. Demir M, Acartürk E, Inal T, et al. Procollagen type I carboxy-
terminal peptide shows left ventricular hypertrophy and dia-
stolic dysfunction in hypertensive patients. Cardiovasc Pathol. 
2007; 16(2): 69–74, doi: 10.1016/j.carpath.2006.09.010, indexed 
in Pubmed: 17317538.
14. Ihm SH, Youn HJ, Shin DI, et al. Serum carboxy-terminal propep-
tide of type I procollagen (PIP) is a marker of diastolic dysfunc-
tion in patients with early type 2 diabetes mellitus. Int J Cardiol. 
2007; 122(3): e36–e38, doi: 10.1016/j.ijcard.2007.07.057, indexed 
in Pubmed: 17920710.
www.cardiologyjournal.org 9
Sylwia Wiśniowska-Śmiałek et al., Fibrosis markers and diastolic dysfunction in dilated cardiomyopathy
15. Roongsritong C, Bradley J, Sutthiwan P, et al. Elevated carboxy-
terminal peptide of procollagen type I in elderly patients with 
diastolic dysfunction. Am J Med Sci. 2006; 331(3): 131–133, 
indexed in Pubmed: 16538073.
16. Roongsritong C, Sadhu A, Pierce M, et al. Plasma carboxy-ter-
minal peptide of procollagen type I is an independent predictor of 
diastolic function in patients with advanced systolic heart failure. 
Congest Heart Fail. 2008; 14(6): 302–306, doi: 10.1111/j.1751-
-7133.2008.00014.x, indexed in Pubmed:19076852.
17. Rossi A, Cicoira M, Golia G, et al. Amino-terminal propeptide of 
type III procollagen is associated with restrictive mitral filling 
pattern in patients with dilated cardiomyopathy: a possible link 
between diastolic dysfunction and prognosis. Heart. 2004; 90(6): 
650–654, indexed in Pubmed: 15145870.
18. Glazer NL, Macy EM, Lumley T, et al. Transforming growth 
factor beta-1 and incidence of heart failure in older adults: the 
Cardiovascular Health Study. Cytokine. 2012; 60(2): 341–345, 
doi: 10.1016/j.cyto.2012.07.013, indexed in Pubmed: 22878343.
19. Hein S, Arnon E, Kostin S, et al. Progression from com-
pensated hypertrophy to failure in the pressure-overloaded 
human heart: structural deterioration and compensatory 
mechanisms. Circulation. 2003; 107(7): 984–991, indexed in 
Pubmed: 12600911.
20. Khan SA, Joyce J, Tsuda T. Quantification of active and total trans-
forming growth factor-b levels in serum and solid organ tissues 
by bioassay. BMC Res Notes. 2012; 5: 636, doi: 10.1186/1756-
0500-5-636, indexed in Pubmed: 23151377.
21. Petrov VV, Fagard RH, Lijnen PJ. Stimulation of collagen produc-
tion by transforming growth factor-beta1 during differentiation of 
cardiac fibroblasts to myofibroblasts. Hypertension. 2002; 39(2): 
258–263, indexed in Pubmed: 11847194.
22. Accornero F, van Berlo JH, Correll RN, et al. Genetic Analysis of 
Connective Tissue Growth Factor as an Effector of Transform-
ing Growth Factor b Signaling and Cardiac Remodeling. Mol 
Cell Biol. 2015; 35(12): 2154–2164, doi: 10.1128/MCB.00199-15, 
indexed in Pubmed: 25870108.
23. Wu CK, Wang YC, Lee JK, et al. Connective tissue growth factor 
and cardiac diastolic dysfunction: human data from the Taiwan 
diastolic heart failure registry and molecular basis by cellu-
lar and animal models. Eur J Heart Fail. 2014; 16(2): 163–172, 
doi: 10.1002/ejhf.33, indexed in Pubmed:24464932.
24. de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac re-
modeling and heart failure. Curr Heart Fail Rep. 2010; 7(1): 1–8, 
doi: 10.1007/s11897-010-0004-x, indexed in Pubmed: 20425490.
25. Wu CK, Su MY, Lee JK, et al. Galectin-3 level and the severity of 
cardiac diastolic dysfunction using cellular and animal models and 
clinical indices. Sci Rep. 2015; 5: 17007, doi: 10.1038/srep17007, 
indexed in Pubmed: 26582585.
26. Gurel OM, Yilmaz H, Celik TH, et al. Galectin-3 as a new biomarker of 
diastolic dysfunction in hemodialysis patients. Herz. 2015; 40(5): 788–
–794, doi:10.1007/s00059-015-4303-6, indexed in Pubmed: 25990624.
27. Michalski B, Trzciński P, Kupczyńska K, et al. The differences 
in the relationship between diastolic dysfunction, selected bio-
markers and collagen turn-over in heart failure patients with pre-
served and reduced ejection fraction. Cardiol J. 2017; 24(1): 35–
42, doi: 10.5603/CJ.a2016.0098, indexed in Pubmed: 27748500.
28. Ommen SR, Nishimura RA, Appleton CP, et al. Clinical utility 
of Doppler echocardiography and tissue Doppler imaging in the 
estimation of left ventricular filling pressures: A comparative 
simultaneous Doppler-catheterization study. Circulation. 2000; 
102(15): 1788–1794, indexed in Pubmed:11023933.
29. Besler C, Lang D, Urban D, et al. Plasma and cardiac galectin-3 
in patients with heart failure reflects both inflammation and fibro-
sis: implications for its use as a biomarker. Circ Heart Fail. 2017; 
10(3), doi: 10.1161/CIRCHEARTFAILURE.116.003804, indexed 
in Pubmed: 28288987.
